Fetal minitoring data were analyzed in 176 labors that developed ominous fetal heart rate deceleration patterns (FHRDP) during the two hours prior to delivery in an effort to identify how neonatal condition could be most accurately predicted. It was found that ominous FHRDP corresponded to a one-minute Apgar score of 6 or less in only 15.3% of cases. When patterns with fetal scalp blood pHs (FSBpH) of less than or equal to 7.20 (n = 18) were considered, 44.4% had an Apgar score of 6 or less. Mean Apgar scores for those neonates who had a pH of less than or equal to 7.20 were significantly less than the mean Apgar score of the control group (p less than 0.001 for all deceleration types). The result reveals that FSBpH has a better predictive value than FHRDP alone for neonatal depression. It is suggested that, as soon as ominous FHRDP occurs during labor, FSBpH be performed to assess not only fetal status but also to predict neonatal outcome.

Apgar Score↗

PubMedDate not supplied

The significance of sinusoidal fetal heart rate pattern during labor and its relation to fetal status and neonatal outcome.

Twenty-seven cases of sinusoidal fetal heart rate were studied. This group had a mean scalp pH of 7.288, significantly lower (p less than 0.005) than that of the control group. The mean one-minute Apgar score was 7.148, significantly lower (p less than 0.001) than the control group's mean score. Almost half (48,15%) of the fetuses had a one-minute Apgar score of 7 or less. Every fetus was viable. Amplitude of the pattern was found to correlate with neonatal depression, the larger the amplitude, the more profound the depression. Over 96% of the fetuses had cord-related deceleration patterns, and nearly 63% had obvious cord complications. It is postulated that sinusoidal patterns are an umbilical cord-related phenomenon, resulting from an alternating hypovolemia and hypervolemia. Clinicians are urged to scrutinize carefully any cases of this pattern, and perform an immediate fetal scalp blood pH determination. If the pH determination obtained is less than 7.25, the authors suggest intervention and operative delivery.

Apgar Score↗

PubMedDate not supplied

Colonic arterial spider in cirrhosis.

Explore the source record for details and available documents.

Aged↗

PubMedDate not supplied

Nucleotide sequence of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, a glycoprotein of endoplasmic reticulum.

The nucleotide sequence of a 4.8-kilobase mRNA for hamster 3-hydroxy-3-methylglutaryl coenzyme A reductase, the endoplasmic reticulum enzyme that controls cholesterol biosynthesis, shows that it is a protein of 887 amino acids (molecular weight 97,092) which contains three potential sites for asparagine-linked glycosylation. The reductase is a transmembrane glycoprotein, but in contrast to many other transmembrane glycoproteins, it lacks a cleavable or hydrophobic NH2-terminal signal sequence.

Amino Acid Sequence↗

PubMedDate not supplied

AIDS agreement.

Explore the source record for details and available documents.

France↗

PubMedDate not supplied

Study of the human auditory cortices using a whole-head magnetometer: left vs. right hemisphere and ipsilateral vs. contralateral stimulation.

Structural and functional asymmetries of the temporal lobe affect language development and may also play a role in a variety of disorders, ranging from specific language impairment to schizophrenia. Whole-head neuromagnetometers allow the noninvasive measurement of functional asymmetries since activity from both hemispheres is recorded simultaneously. In the present study, the location of the auditory cortices and their responsiveness to pure tones was compared between hemispheres in healthy human subjects. Data suggest a greater contralateral than ipsilateral activation. In line with previous findings, sources of responses for the right hemisphere seem to be more anterior than for the left one.

Acoustic Stimulation↗

PubMedDate not supplied

Intra-articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: a pilot study.

OBJECTIVES: This study was undertaken to assess the safety and potential efficacy of intra-articular non-animal stabilised hyaluronic acid (NASHA) in patients with hip OA. METHODS: This was a prospective, open-label, 3-month pilot study of a single intra-articular injection of NASHA in 31 patients. Safety outcomes were measured at 2 weeks and 3 months after treatment, as were efficacy measurements including WOMAC pain, stiffness and physical function scores, and the patient assessment of global disease status. Patients demonstrating reduced pain at month 3 participated in an extension phase (assessment at 6-11 months, 18 patients). Positive response was defined as a > or = 40% reduction in the WOMAC pain score from baseline, together with an absolute decrease of > or = 5 points. RESULTS: Intra-articular injection of NASHA into the hip was well tolerated. The only treatment-related AE was exacerbation of pain and/or stiffness in the treated hip (reported by 9 patients) and there were no serious AEs. The response rate to treatment was 50% at 2 weeks and 54% at 3 months. In the extension population, response rates of 69% and 44% were observed at month 3 and the extension visit, respectively. Global disease status was improved at month 3 compared with baseline in 68% of the patients. CONCLUSIONS: Our results show that a single intra-articular injection of NASHA is a well tolerated and potentially effective therapy in the treatment of hip OA. Further studies of NASHA in this setting are warranted.

Adjuvants, Immunologic↗

PubMedDate not supplied

No demonstrable effect of sobrerol as an expectorant in patients with stable chronic bronchial diseases.

A randomized double-blind cross-over study compared the clinical effectiveness of a 14-day treatment with 400 mg X day-1 of sobrerol and placebo in 23 patients with stable chronic bronchial disease. During the seven week trial, subjective symptoms and findings (cough frequency and severity, difficulty in raising sputum, dyspnoea) were recorded, pulmonary function tests performed and sputum physical characteristics (24-h sputum volume, purulence, cell concentration, protein, sputum dry weight and "apparent" viscosity) determined on a regular basis. Side-effects were closely monitored. Both subjective assessment of overall clinical efficacy as well as statistical analysis of the above mentioned factors failed to show any significant advantage of sobrerol to placebo--except for a transient decrease of the 24-h sputum volume. Sobrerol appears to be another example of an expectorant lacking evidence of clinical effectiveness in the management of chronic bronchial secretions.

Bronchial Diseases↗

PubMedDate not supplied

[A new example of anti-platelet antibody Ko].

Explore the source record for details and available documents.

Blood Platelets↗